摘要
目的:观察注射用羟基红花黄色素A(HSYA)对家兔血小板聚集功能及超微结构的影响。方法:采用体内实验法,观察3种剂量的注射用HSYA(10、5和2.5mg/kg)对由花生四烯酸(AA)、二磷酸腺苷(ADP)和血小板活化因子(PAF)(3.6nmol/L)诱导的家兔血小板聚集作用的影响,以及血小板超微结构的变化;并单独研究了以PAF为诱导剂的情况下,富血小板血浆(PRP)中α-颗粒膜蛋白-140(GMP-140)的含量。结果:各剂量HSYA注射剂能抑制AA、PAF诱导的家兔血小板聚集(P<0.05,P<0.01);扫描电镜显示:各剂量HSYA注射剂能减少AA和PAF诱导后的聚集型血小板数量并使树突型血小板突起变少变短(P<0.05,P<0.01);另外,各剂量HSYA注射剂还能降低经PAF诱导后GMP-140的含量(P<0.01)。结论:注射用羟基红花黄色素A具有显著的抗PAF诱导的血小板聚集作用,抑制血小板的活化,从而为临床抗血小板聚集药物的使用提供更多选择。
To observe the effects of HSYA injection on platelet aggregation and ultra structure in rabbits. METHODS: In vivo experi- ments, when platelet activating factor (PAF) induced respectively, we observed the impacts of HSYA injection (10 mg/kg, 5 mg/kg and 2. 5 mg/kg) on platelet aggregation, ultra structural changes of platelets and PAF-induced content of GMP-140. RESULTS: HSYA injection inhibited AA and PAF-induced platelet aggregation(P〈 0.05,P〈 0.01). Scanning electron microscope showed: HSYA injection could reduce the num- ber of aggregation type plateles which were in- duced by AA and PAF; and make fewer andshorter processes of dendritic platelets (P 0. 05 , P〈0. 01). HSYA injection can reduce the content of GMP-140 in PRP(P〈0.01). CON- CLUSION: HSYA injection can antagonism PAF-induced platelet aggregation, inhibit the activation of platelets and reduce the content of GMP-140. Thus for, there will be more choices for clinical using of anti-platelet aggregation drugs.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第3期269-273,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics